文献速递消化道肿瘤与早癌消化内镜

利用异常循环游离线粒体DNA片段组学特征早期检测结直肠癌

Early detection of colorectal cancer using aberrant circulating cell-free mitochondrial DNA fragmentomics.
PubMed 文献 · Gut · 2025-05-07

研究纳入1147名参与者(478名健康对照、112名进展期腺瘤患者和557名结直肠癌患者),来自五家医院,采集血浆进行基于捕获的循环游离线粒体DNA测序。基于片段组学特征构建的结直肠癌检测模型在训练队列中曲线下面积为0.9863,灵敏度92.68%,特异度93.45%,内部和两个外部验证队列均显示能区分早期结直肠癌与健康对照,并可在进展期腺瘤队列中分别达到79.35%和85.00%的灵敏度。

要点

  • 基于循环游离线粒体DNA片段组学特征构建的结直肠癌检测模型在训练队列中曲线下面积为0.9863。
  • 该模型在训练队列中灵敏度为92.68%,特异度为93.45%。
  • 该模型在进展期腺瘤队列1中灵敏度为79.35%,在进展期腺瘤队列2中为85.00%。

核心结论

  • 基于异常循环游离线粒体DNA片段组学特征,建立了一种新型无创方法,用于检测早期结直肠癌或进展期腺瘤患者,具有高性能。

研究设计与样本

  • 共纳入1147名参与者,包括478名健康对照、112名进展期腺瘤患者和557名结直肠癌患者,来自五家医院,采集血浆样本进行基于捕获的循环游离线粒体DNA测序。

主要发现

  • 与健康对照相比,结直肠癌和进展期腺瘤患者的循环游离线粒体DNA片段组学特征显著异常。
  • 基于246例结直肠癌患者和168名健康对照的训练队列构建结直肠癌检测模型,曲线下面积为0.9863,灵敏度为92.68%,特异度为93.45%。
  • 内部验证和两个外部验证队列均证明该模型在区分早期结直肠癌患者与健康对照方面具有出色能力,大幅超越血清生物标志物的性能。
  • 该模型在进展期腺瘤队列1中检测灵敏度为79.35%,在进展期腺瘤队列2中为85.00%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Early detection of colorectal cancer (CRC) is crucial for improving the survival rates of patients. OBJECTIVE: We aimed to develop a novel strategy for early CRC detection using the fragmentomic features of circulating cell-free mitochondrial DNA (ccf-mtDNA). DESIGN: Here, a total of 1147 participants, including 478 healthy controls (HCs), 112 patients with advanced adenomas (AAs) and 557 patients with CRC, were enrolled from five hospitals and plasma samples were collected for capture-based ccf-mtDNA sequencing. RESULTS: Our data analysis revealed significantly aberrant ccf-mtDNA fragmentomic features in patients with CRC and AA when compared with HCs. Then, a CRC detection (CD) model was constructed based on the fragmentomic features of ccf-mtDNA from 246 patients with CRC and 168 HC in the training cohort, showing area under the curve of 0.9863, sensitivity of 92.68% and specificity of 93.45%. Both internal and two external validation cohorts demonstrated the excellent capacity of CD model in distinguishing patients with early-stage CRC from HCs, greatly surpassing the performance of serum biomarkers. Furthermore, our CD model can also detect patients with AA with a sensitivity of 79.35% in AA cohort 1 and 85.00% in AA cohort 2. CONCLUSION: In conclusion, based on aberrant ccf-mtDNA fragmentomic features, a novel and non-invasive approach was established for the detection of patients with early-stage CRC or AA, with high performance.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Wang S, Peng F, Dang M, et al. Early detection of colorectal cancer using aberrant circulating cell-free mitochondrial DNA fragmentomics. Gut. 2025. PMID: 39694683. doi:10.1136/gutjnl-2024-333533

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。